Amphastar Pharmaceuticals (AMPH) Presents At Jefferies 2019 Healthcare Conference - Slideshow

Company Overview - Amphastar is a specialty pharmaceutical company focused on technically challenging generic and proprietary injectable and inhalation products[31] - The company is vertically integrated from R&D to clinical trials, manufacturing, marketing and distribution[6] - The company has over 2,000 employees and 1.9 million square feet of facilities[6] Financial Performance - The company had approximately $295 million in revenue in 2018[31] - The company had approximately $107 million in gross profit in 2018[31] - Enoxaparin sales were approximately $53 million in 2018[6] Pipeline and R&D - The company has a robust pipeline of over 20 product candidates in attractive markets[31] - The company has 290 employees dedicated to R&D[7, 12] - The company has four filed ANDAs with IQVIA sales of approximately $800 million[13] - The company has five injectable ANDAs in development targeting products with IQVIA sales of approximately $4 billion[13] - The company has six inhalation ANDAs in development targeting products with IQVIA sales of approximately $10 billion[13] - The company has injectable biosimilars in development targeting products with IQVIA sales of approximately $14 billion[14]